AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29200185 — intervention group
Group type: EXPERIMENTAL
Intervention: AOM of other bacterial etiology
Number of subjects: 831
Study 29200185 — intervention group
Group type: COMPARATOR
Intervention: No bacteria detected at AOM
Number of subjects: 831
Study 29200185 — intervention group
Group type: COMPARATOR
Intervention: No early AOM
Number of subjects: 831
Study 27509949 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioguided occult lesion localization (ROLL)
Number of subjects: 60
Study 27509949 — intervention group
Group type: COMPARATOR
Intervention: Wire guided localization (WGL)
Number of subjects: 60
Study 27509949 — intervention group
Group type: EXPERIMENTAL
Intervention: ROLL
Number of subjects: 60
Study 27509949 — intervention group
Group type: COMPARATOR
Intervention: WGL
Number of subjects: 60
Study 24767575 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care with additional inspiratory muscle training intervention
Number of subjects: 248
Study 24767575 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 248
Study 22844527 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma CatS levels (total, active, and pro‐CatS) in AAA patients
Number of subjects: 676
Study 22844527 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma cystatin C levels in AAA patients
Number of subjects: 676
Study 22844527 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of plasma CatS levels with aortic diameter and lowest ABI
Number of subjects: 676
Study 22844527 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of plasma cystatin C levels with aortic diameter and lowest ABI
Number of subjects: 676
Study 20346181 — intervention group
Group type: EXPERIMENTAL
Intervention: Bojungikgitang
Number of subjects: 0
Study 20346181 — intervention group
Group type: EXPERIMENTAL
Intervention: Banhabaekchulchonmatang
Number of subjects: 0
Study 20346181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18653285 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg memantine
Number of subjects: 10
Study 18653285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 15982350 — intervention group
Group type: EXPERIMENTAL
Intervention: One dose of influenza vaccine
Number of subjects: 70
Study 15982350 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of influenza vaccine
Number of subjects: 70
Study 12816768 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (HP diet: 27% energy as protein, 44% as carbohydrate, 29% as fat)
Number of subjects: 57
Study 9836012 — intervention group
Group type: EXPERIMENTAL
Intervention: D-serine (30 mg/kg/day)
Number of subjects: 31
Study 9836012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 7633106 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast spin-echo (FSE) technique
Number of subjects: 25
Study 7633106 — intervention group
Group type: COMPARATOR
Intervention: Conventional spin-echo (CSE) technique
Number of subjects: 25
Study 2923957 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0
Study 2923957 — intervention group
Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 0
Study 979226 — intervention group
Group type: EXPERIMENTAL
Intervention: Active recuperation (300 kpm/min)
Number of subjects: 13
Study 979226 — intervention group
Group type: COMPARATOR
Intervention: Passive recuperation (quiet sitting)
Number of subjects: 13
Study 29150782 — intervention group
Group type: EXPERIMENTAL
Intervention: GN2O (70% N2O in 30% oxygen)
Number of subjects: 100
Study 29150782 — intervention group
Group type: COMPARATOR
Intervention: GO2 (air in 30% oxygen)
Number of subjects: 100
Study 29150782 — intervention group
Group type: EXPERIMENTAL
Intervention: GN2O
Number of subjects: 100
Study 26837431 — intervention group
Group type: EXPERIMENTAL
Intervention: Early home-supported discharge service
Number of subjects: 190
Study 26837431 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 190
Study 25782764 — intervention group
Group type: EXPERIMENTAL
Intervention: GLYX-13 (5 or 10 mg/kg IV)
Number of subjects: 116
Study 25782764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study 23650780 — intervention group
Group type: EXPERIMENTAL
Intervention: BOMT1 (Bismuth citrate 2 x 600 mg, omeprazole 2 x 20 mg, metronidazole 2 x 500 mg, tetracycline 2 x 500 mg; for 14 days)
Number of subjects: 90
Study 23650780 — intervention group
Group type: EXPERIMENTAL
Intervention: BOMT2 (Bismuth citrate 2 x 600 mg, omeprazole 2 x 20 mg, metronidazole 3 x 500 mg, tetracycline 4 x 500 mg; for 14 days)
Number of subjects: 90
Study 21085598 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-vocal test tones (piano and pure tones)
Number of subjects: 0
Study 21085598 — intervention group
Group type: COMPARATOR
Intervention: Vocal test tones (natural and synthesized voices)
Number of subjects: 0
Study 21085598 — intervention group
Group type: EXPERIMENTAL
Intervention: Starting music lessons by age 7
Number of subjects: 0
Study 21085598 — intervention group
Group type: EXPERIMENTAL
Intervention: Starting music lessons on piano at a later age
Number of subjects: 0
Study 17626135 — intervention group
Group type: EXPERIMENTAL
Intervention: Forearm support board
Number of subjects: 206
Study 17626135 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative mouse
Number of subjects: 206
Study 17626135 — intervention group
Group type: COMPARATOR
Intervention: Conventional mouse
Number of subjects: 206
Study 17626135 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative mouse plus forearm support board
Number of subjects: 206
Study 16337372 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous carboplatin
Number of subjects: 0
Study 16337372 — intervention group
Group type: COMPARATOR
Intervention: Treosulfan
Number of subjects: 0
Study 14761119 — intervention group
Group type: EXPERIMENTAL
Intervention: Juvenile idiopathic arthritis (JIA)
Number of subjects: 32
Study 14761119 — intervention group
Group type: COMPARATOR
Intervention: Control group (CTR)
Number of subjects: 32
Study 11289483 — intervention group
Group type: EXPERIMENTAL
Intervention: NPH insulin combined with glibenclamide (n = 19)
Number of subjects: 81
Study 11289483 — intervention group
Group type: EXPERIMENTAL
Intervention: NPH insulin combined with metformin (n = 17)
Number of subjects: 81
Study 11289483 — intervention group
Group type: EXPERIMENTAL
Intervention: NPH insulin combined with glibenclamide and metformin (n = 17)
Number of subjects: 81
Study 11289483 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning administration of NPH insulin (n = 23)
Number of subjects: 81
Study 11289483 — intervention group
Group type: EXPERIMENTAL
Intervention: NPH insulin therapy
Number of subjects: 81
Study 9272791 — intervention group
Group type: EXPERIMENTAL
Intervention: Phantom limb pain
Number of subjects: 32
Study 9272791 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesthetic and kinetic phantom limb sensations
Number of subjects: 32
Study 9272791 — intervention group
Group type: EXPERIMENTAL
Intervention: Stump pain
Number of subjects: 32
Study 9272791 — intervention group
Group type: EXPERIMENTAL
Intervention: Telescoping of phantom limb
Number of subjects: 32
Study 8153780 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 20
Study 8153780 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% etidocaine
Number of subjects: 20
Study 3217756 — intervention group
Group type: EXPERIMENTAL
Intervention: S-adenosyl-L-methionine (SAMe) 800 mg/day
Number of subjects: 10
Study 3217756 — intervention group
Group type: EXPERIMENTAL
Intervention: S-adenosyl-L-methionine (SAMe) 200 mg/day
Number of subjects: 10
Study 3217756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 1858634 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill tests (Bruce, Balke, and ramp)
Number of subjects: 23
Study 1858634 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycle ergometer tests (50 W/stage, 25 W/stage, and ramp)
Number of subjects: 23
Study 1858634 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in protocol
Number of subjects: 23
Study 1858634 — intervention group
Group type: EXPERIMENTAL
Intervention: V slope method of detection
Number of subjects: 23
Study 1858634 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall intraclass correlation coefficient for VO2 at the ATge among three reviewers
Number of subjects: 23
Study 1858634 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall intraclass correlation coefficient for VO2 at the ATge among three protocols
Number of subjects: 23
Study 409824 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose continuous intravenous insulin infusion
Number of subjects: 20
Study 409824 — intervention group
Group type: COMPARATOR
Intervention: High-dose intermittent subcutaneous injections
Number of subjects: 20
Study 31907018 — intervention group
Group type: COMPARATOR
Intervention: Routine antenatal ultrasound scan < 25 weeks during routine care and a second standard ultrasound scan at the research site within 2 weeks.
Number of subjects: 100
Study 31907018 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine antenatal ultrasound scan and an additional ultrasound scan < 25 weeks at the research site, with messages to promote parental attachment and healthy child development.
Number of subjects: 100
Study 31907018 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine ultrasound scan and two additional ultrasound scans at the research site, < 25 weeks and < 36 weeks, with messages to promote parental attachment and healthy child development.
Number of subjects: 100
Study 30759112 — intervention group
Group type: EXPERIMENTAL
Intervention: High religiosity (attending religious services or activities at least 1-2 times a month)
Number of subjects: 20227
Study 30759112 — intervention group
Group type: COMPARATOR
Intervention: Low religiosity
Number of subjects: 20227
Study 30678594 — intervention group
Group type: EXPERIMENTAL
Intervention: Nested polymerase chain reaction (PCR) assay using six sets of primers developed from 20 candidate genes of U. virens.
Number of subjects: 0
Study 26266877 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 24
Study 26266877 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (active placebo)
Number of subjects: 24
Study 23974642 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafamidis 20 mg once daily
Number of subjects: 86
Study 23974642 — intervention group
Group type: COMPARATOR
Intervention: Placebo (switched to tafamidis)
Number of subjects: 86
Study 23974642 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafamidis for 30 months
Number of subjects: 86
Study 23974642 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafamidis
Number of subjects: 86
Study 21419776 — intervention group
Group type: EXPERIMENTAL
Intervention: Canary pox recombinant vaccine
Number of subjects: 44
Study 21419776 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole inactivated vaccines
Number of subjects: 44
Study 21419776 — intervention group
Group type: EXPERIMENTAL
Intervention: Subunit vaccines
Number of subjects: 44
Study 21419776 — intervention group
Group type: EXPERIMENTAL
Intervention: All vaccines
Number of subjects: 44
Study 21419776 — intervention group
Group type: COMPARATOR
Intervention: Annual vaccination
Number of subjects: 44
Study 21419776 — intervention group
Group type: EXPERIMENTAL
Intervention: Revaccination of horses with low antibody levels
Number of subjects: 44
Study 19195817 — intervention group
Group type: COMPARATOR
Intervention: 4 cycles of epirubicin 75 mg/m² and docetaxel 75 mg/m²
Number of subjects: 176
Study 19195817 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 cycles of epirubicin 75 mg/m² and docetaxel 75 mg/m²
Number of subjects: 176
Study 17572614 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual outpatient physiotherapy
Number of subjects: 212
Study 17572614 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal stabilization classes
Number of subjects: 212
Study 17572614 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapist-led pain management classes
Number of subjects: 212
Study 15084646 — intervention group
Group type: EXPERIMENTAL
Intervention: Mentholated cigarettes
Number of subjects: 14
Study 15084646 — intervention group
Group type: COMPARATOR
Intervention: Nonmentholated cigarettes
Number of subjects: 14
Study 11583478 — intervention group
Group type: EXPERIMENTAL
Intervention: GW420867X 300 mg
Number of subjects: 4
Study 11583478 — intervention group
Group type: EXPERIMENTAL
Intervention: GW420867X 600 mg
Number of subjects: 4
Study 11583478 — intervention group
Group type: EXPERIMENTAL
Intervention: GW420867X 900 mg
Number of subjects: 4
Study 11583478 — intervention group
Group type: EXPERIMENTAL
Intervention: GW420867X 1200 mg
Number of subjects: 4
Study 11583478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 9885721 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure garment
Number of subjects: 0
Study 9885721 — intervention group
Group type: COMPARATOR
Intervention: No pressure garment (Control)
Number of subjects: 0
Study 8299786 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg of conjugated oral estrogen
Number of subjects: 35
Study 8299786 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg transdermal 17 beta‐E2
Number of subjects: 35
Study 2607268 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 ml of 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 30
Study 2607268 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.6 ml of 2% lidocaine with 1:200,000 epinephrine
Number of subjects: 30
Study 2607268 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 ml of 4% lidocaine with 1:100,000 epinephrine
Number of subjects: 30
Study 2607268 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete anesthesia
Number of subjects: 30
Study 2607268 — intervention group
Group type: EXPERIMENTAL
Intervention: Potential anesthetic problems
Number of subjects: 30
Study 30684002 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose RAI therapy (3700 MBq)
Number of subjects: 84
Study 30684002 — intervention group
Group type: COMPARATOR
Intervention: Low-dose RAI therapy (1110 MBq)
Number of subjects: 84
Study 28632666 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Intensity Pulsed Ultrasound (LIPUS) treatment for 2 minutes a day at 100 KHz frequency
Number of subjects: 19
Study 28632666 — intervention group
Group type: COMPARATOR
Intervention: Non-treated side (control)
Number of subjects: 19
Study 25884517 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Health First Aid (MHFA) course, two days duration
Number of subjects: 500
Study 25884517 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (no intervention for 6 months)
Number of subjects: 500
Study 23587561 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone app (My Meal Mate)
Number of subjects: 128
Study 23587561 — intervention group
Group type: COMPARATOR
Intervention: Website (Weight Loss Resources)
Number of subjects: 128
Study 23587561 — intervention group
Group type: COMPARATOR
Intervention: Paper diary
Number of subjects: 128
Study 21570487 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise combined with vitamin D and calcium supplements
Number of subjects: 60
Study 21570487 — intervention group
Group type: COMPARATOR
Intervention: Control group (advised on benefits of exercise but not prescribed exercise)
Number of subjects: 60
Study 19694184 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice (GFJ) 200 ml three times a day for four days with 3 mg budesonide as ER capsules
Number of subjects: 8
Study 19694184 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice (GFJ) 200 ml three times a day for four days with 3 mg budesonide as plain capsules
Number of subjects: 8
Study 19694184 — intervention group
Group type: COMPARATOR
Intervention: Budesonide (3 mg) without grapefruit juice
Number of subjects: 8
Study 16973647 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2%, 1 ml kg(‐1) with fentanyl 1 microg kg(‐1)
Number of subjects: 36
Study 16973647 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 0.2%, 1 ml kg(‐1) with saline
Number of subjects: 36
Study 12720586 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythorbic acid (1 g)
Number of subjects: 20
Study 12720586 — intervention group
Group type: COMPARATOR
Intervention: Ascorbic acid supplementation (0.5 g/d for 2 weeks)
Number of subjects: 20
Study 12720586 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 20
Study 11139102 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion (0.1 microg/kg/min) plus intrathecal morphine (8 microg/kg)
Number of subjects: 40
Study 11139102 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil infusion (0.3 microg/kg/h)
Number of subjects: 40
Study 11139102 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion plus intrathecal morphine
Number of subjects: 40
Study 11139102 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil infusion
Number of subjects: 40
Study 9417395 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine 50 mg, abrupt or progressive withdrawal
Number of subjects: 154
Study 9417395 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine 25 mg, abrupt or progressive withdrawal
Number of subjects: 154
Study 9417395 — intervention group
Group type: COMPARATOR
Intervention: Placebo, abrupt or progressive withdrawal
Number of subjects: 154
Study 9417395 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrupt withdrawal (with or without hydroxyzine)
Number of subjects: 154
Study 9417395 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive withdrawal (with or without hydroxyzine)
Number of subjects: 154
Study 1348430 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroleptic treatment (dosage changed)
Number of subjects: 0
Study 4064575 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral high-frequency oscillation (OHFO)
Number of subjects: 0
Study 4064575 — intervention group
Group type: EXPERIMENTAL
Intervention: External chest wall compression (ECWC)
Number of subjects: 0
Study 31161347 — intervention group
Group type: EXPERIMENTAL
Intervention: GDF-15 (increased levels)
Number of subjects: 1184305
Study 30045274 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge-based iterative model reconstruction (IMR)
Number of subjects: 101
Study 30045274 — intervention group
Group type: COMPARATOR
Intervention: Filtered back projection (FBP)
Number of subjects: 101
Study 30045274 — intervention group
Group type: COMPARATOR
Intervention: Hybrid iterative reconstruction (HIR)
Number of subjects: 101
Study 30045274 — intervention group
Group type: EXPERIMENTAL
Intervention: IMR with reduced tube voltage (80 kVp)
Number of subjects: 101
Study 30045274 — intervention group
Group type: EXPERIMENTAL
Intervention: IMR at 100 kVp
Number of subjects: 101
Study 30045274 — intervention group
Group type: COMPARATOR
Intervention: Standard 120-kVp protocol
Number of subjects: 101
Study 26054422 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Cognition and Interaction Training (SCIT)
Number of subjects: 36
Study 26054422 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 36
Study 25530160 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal capsaicin injection at 1 mm depth
Number of subjects: 15
Study 25530160 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal capsaicin injection at 3 mm depth
Number of subjects: 15
Study 25530160 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal capsaicin injection at 5 mm depth
Number of subjects: 15
Study 25530160 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal capsaicin injection at 7 mm depth
Number of subjects: 15
Study 22955340 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating 25-hydroxyvitamin D (25(OH)D)
Number of subjects: 490
Study 22955340 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating 1,25-dihydroxyvitamin D (1,25(OH)2D)
Number of subjects: 490
Study 22955340 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D pathway polymorphisms
Number of subjects: 490
Study 22955340 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratified results by prostate cancer grade (high grade or low grade)
Number of subjects: 490
Study 20456970 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction aortoplasty with patch augmentation
Number of subjects: 66
Study 20456970 — intervention group
Group type: COMPARATOR
Intervention: Modified David type repair with patch augmentation
Number of subjects: 66
Study 17900775 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 101
Study 17900775 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 101
Study 17900775 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 101
Study 17900775 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 101
Study 15929047 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparse pattern pulse stimulation for dichoptic multifocal visual evoked potentials (mfVEPs)
Number of subjects: 77
Study 15929047 — intervention group
Group type: COMPARATOR
Intervention: Conventional mfVEP stimulus
Number of subjects: 77
Study 15929047 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparse mfVEPs
Number of subjects: 77
Study 15929047 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast reversal
Number of subjects: 77
Study 12850864 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin, 850 mg twice daily throughout the cycle
Number of subjects: 161
Study 12850864 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic ovarian drilling
Number of subjects: 161
Study 10483810 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue protocol consisting of 30 isometric maximal voluntary contractions (5s on, 5s off) followed by three maximal isometric knee extensions.
Number of subjects: 19
Study 8998891 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac (60 mg followed by 30 mg)
Number of subjects: 244
Study 8998891 — intervention group
Group type: COMPARATOR
Intervention: Meperidine (100 mg or placebo)
Number of subjects: 244
Study 8998891 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 244
Study 2007041 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg IV
Number of subjects: 80
Study 2007041 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg IV and Metoclopramide 10 mg IV
Number of subjects: 80
Study 2007041 — intervention group
Group type: COMPARATOR
Intervention: Control (Group 1 and Group 2)
Number of subjects: 80